---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-003217"
form_type: "8-K"
ticker: "CPMV"
cik: "0000836564"
company_name: "Mosaic ImmunoEngineering Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:10:12.862366+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mosaic ImmunoEngineering secures exclusive worldwide CPMV license from Case Western Reserve University

## Summary
- Licensed technology covers cowpea mosaic virus (CPMV)-based oncology treatments for human and companion animal cancers.
- Development milestone payments up to $1.8M per human product; tiered royalties starting in mid-single digits on net sales.
- Annual minimum royalty of $10,000 starting year 2, rising based on net sales; CWRU to be reimbursed ~$278K in IP fees.
- Agreement term runs 20 years or last patent expiry; Mosaic gains rights to core technology behind lead candidate MIE-101.

## SEC filing metadata
- accession: 0001683168-22-003217
- form_type: 8-K
- ticker: CPMV
- cik: 0000836564
- company_name: Mosaic ImmunoEngineering Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/836564/000168316822003217/0001683168-22-003217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/836564/000168316822003217/mosiac_8k-050422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-003217
- JSON: https://secwatch.observer/filing/0001683168-22-003217.json
- Plain text: https://secwatch.observer/filing/0001683168-22-003217.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.